你是 stock-analyst v20 DD 的證據採集子 agent。標的：DXCM。
你負責下列 1 個覆蓋軸，逐軸獨立查證，**本軸最多 3 次 WebSearch**（每一類題目一次），查不到就記 none，不要一直挖。

[regulatory_antitrust] 法規／反壟斷
Q: 本標的是否面臨反壟斷調查、拆分風險或產業特定監管新規？
  - DXCM DexCom antitrust OR monopoly investigation 2026
  - DexCom regulation OR regulatory scrutiny Medical Devices 2026
  - DXCM DexCom DOJ OR FTC OR EU competition 2026
  (na_allowed=true)


## 規則（嚴格遵守，違反視為無效輸出）
1. **只回 sourced claim**：每條 finding 必須有可查證的 source（URL 或明確可搜尋到的來源名＋標題）與 as_of（該資訊的發布/生效日期，非你查詢的日期）。
2. **查不到就 status="none"**，並列出你實際下過的 queries_run（至少 1 條，需與你實際搜尋詞一致，不得事後編造）。軸清單裡的 `queries` 是起點不是配額，同一次搜尋的來源可同時支撐多個軸。**不得因為查無所獲就用訓練知識/常識填 claim。**
3. **三種狀態不得混用**：found＝有 sourced claim；none＝軸適用於本標的業態、但搜尋查無來源；not_applicable＝該軸對本標的業態根本不成立（例：銀行沒有「最大客戶導入第二供應商」、零售商的客戶是終端消費者）。**軸對此業態不適用時回 not_applicable 並在 note 寫理由，不要回 none。**只有軸物件標 na_allowed=true 才可回 not_applicable，沒標的軸只能 found 或 none；拿不準是否適用就當適用、照常搜尋，不要用 not_applicable 省搜尋。
4. **不臆測、不外推**：claim 只寫你實際找到的事實，不要自己推論「這意味著」，那是判斷層的工作。
5. direction 欄：這條 finding 對本標的是正面(+)／中性(0)／負面(-)，僅標事實方向，不要寫成裁決語。
6. affects 欄：這條 finding 影響哪些判斷面（可填 moat_trend／thesis.H／thesis.R／decision_inputs.bear／valuation／triggers 等，可複選）。
7. **現價一律引 `numbers.price_at_dd`／`price_as_of`，不得自行寫「現價」數字**：市值、距 52 週高低點 %、目標價 vs 現價，一律引用該欄，不從聚合站另抓現價字面數字。
8. **原始證據與解讀分開存**：每條 finding 另填三欄——`url`（實際讀到的網址，沒有就填 null）、`excerpt`（從該來源**逐字複製**、支撐 claim 的原文，≤300 字，不得改寫或翻譯）、`excerpt_from`（`snippet`＝搜尋摘要／`page`＝WebFetch 讀到的頁面）。`claim` 是你對原文的精簡轉述；`excerpt` 是證據本身。找不到可逐字複製的原文就填 null，不要自己寫一句當原文。

## 程式已抓好的一手文件摘錄（本軸）
以下為程式抓取的一手文件摘錄，可直接逐字引用（附 url 與 as_of）：
- 引用時 finding 的 `url`、`as_of` 照該則標示填；`source` 寫「來源＋文件」；`excerpt` 從「<<<」「>>>」之間**逐字複製**（≤300 字，取最能支撐 claim 的連續一段，不改寫、不翻譯）；`excerpt_from` 填 `"page"`。
- 一手清單顯示沒有某類事件時（例如「標題含關鍵字者 0 則」），可據此寫一條「經查一手紀錄無此類事件」的 finding（status=found、direction=`"0"`），excerpt 用清單本身那一句統計；不要因為沒找到事件就標 none。
- 這些摘錄不算你的搜尋：`queries_run` 只記你自己實際下過的搜尋；摘錄仍可另外搜尋補充，但不必為了湊證據重搜摘錄已涵蓋的內容。
- 摘錄與本軸問題無關或不足以回答時，照常搜尋；仍查不到才記 none。

[1] 來源：SEC EDGAR｜文件：10-K（FY2025，申報 2026-02-12）｜章節：Item 3. Legal Proceedings｜url：https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm｜as_of：2026-02-12
<<<
ITEM 3 - LEGAL PROCEEDINGS
We are subject to various claims, complaints and legal actions that arise from time to time in the normal course of business, including commercial insurance, product liability, intellectual property and employment related matters. In addition, from time to time we may bring claims or initiate lawsuits against various third parties with respect to matters arising out of the ordinary course of our business, including commercial and employment related matters.
Securities Class Actions
Between August 21 and October 9, 2024, three substantially similar putative class action complaints were filed against us and certain of our executive officers in the United States District Court for the Southern District of California. On December 13, 2024, the court appointed lead plaintiff and consolidated the three actions (now captioned In re Dexcom, Inc. Class Action Securities Litigation, Lead Case No.: 24-cv-1485-RSH-VET). On January 27, 2025, lead plaintiff filed a consolidated complaint. The consolidated complaint alleges violations of the Exchange Act against us and certain of our current and former executive officers for allegedly making false and misleading statements between April 28, 2023 and July 25, 2024, with respect to our expected revenue for fiscal 2024 and ability to capitalize on our growth potential. On March 13, 2025, we filed a motion to dismiss the consolidated complaint. On May 14, 2025, the court granted the motion to dismiss with leave to amend. On May 28, 2025, lead plaintiff filed an amended consolidated complaint. On June 11, 2025, we filed a motion to dismiss the amended consolidated complaint. On September 9, 2025, the court granted in part and denied in part the motion to dismiss. On October 7, 2025, defendants answered the amended consolidated complaint. On October 10, 2025, defendants filed a motion for judgment on the pleadings as to the two surviving challenged statements. On January 7, 2026, the court granted defendants’ motion for judgment on the pleadings with leave to amend. On February 6, 2026, lead plaintiff filed a second amended consolidated complaint. Defendants’ deadline to respond to the second amended consolidated complaint is February 20, 2026.…
>>>

[2] 來源：SEC EDGAR｜文件：10-K（FY2025，申報 2026-02-12）｜章節：Item 1. Business｜url：https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm｜as_of：2026-02-12
<<<
There are numerous other laws, regulations and legislative and regulatory initiatives at the federal and state levels addressing privacy and security of personal information. We also remain subject to federal and state privacy-related laws that may be more restrictive or contain different requirements than the privacy regulations issued under HIPAA. These laws vary and could impose additional penalties. For example, the Federal Trade Commission, or FTC, uses its consumer protection authority to initiate enforcement actions against companies relating to their use and disclosure of personally identifiable information. Specifically, FTC has asserted authority and issued enforcement actions in response to actual or perceived unfair or deceptive practices by a company in the handling of consumer 21 information. The FTC has also pursued enforcement actions against companies for violations of its Health Breach Notification Rule and the Children’s Online Privacy Protection Act. Our use of personal information is also subject to our published privacy policies and notices.
>>>

[3] 來源：SEC EDGAR｜文件：10-K（FY2025，申報 2026-02-12）｜章節：Item 1A. Risk Factors｜url：https://www.sec.gov/Archives/edgar/data/1093557/000109355726000027/dxcm-20251231.htm｜as_of：2026-02-12
<<<
The FDA, CMS, OIG, OCR, FTC, Department of Justice, states’ attorneys general and other governmental authorities actively enforce the laws and regulations discussed above. In the United States, medical device manufacturers have been the target of numerous government prosecutions and investigations alleging violations of law, including claims asserting impermissible off-label promotion of medical devices, payments intended to influence the referral of federal or state healthcare business, and submission of false claims for government reimbursement. While we make every effort to comply with applicable laws, we cannot rule out the possibility that the government or other third parties could interpret these laws differently and challenge our practices under one or more of these laws. This likelihood of allegations of non-compliance is increased by the fact that under certain federal and state laws applicable to our business, individuals may bring an action on behalf of the government alleging violations of such laws, and potentially be awarded a share of any damages or penalties ultimately awarded to the applicable government body.

The FDA and the FTC share oversight of medical device promotion. The FDA has broad authority over device marketing (including assessment and oversight of safety and effectiveness) and over FDA-approved “promotional labeling,” while the FTC has authority over “advertising” for most medical devices (i.e., non-“restricted” devices, such as ours).

Healthcare companies are subject to numerous investigations and inquiries by various governmental agencies. Further, under the False Claims Act, private parties have the right to bring qui tam, or “whistleblower,” suits against companies that submit false claims for payments to, or improperly retain overpayments from, the government. Some states have adopted similar state whistleblower and false claims provisions. Depending upon whether the underlying conduct alleged in such inquiries or investigations could be considered systemic, any resolution of any such investigations could have a material, adverse effect on our financial position and results of operations.

Our marketing, promotional and educational materials and practices are subject to FDCA, Federal Trade Commission Act, and other applicable laws and regulations, as may be amended from time to time. If the FDA, FTC or other regulatory body with competent jurisdiction over us, our activities or products takes the position that our marketing, promotional or other materials or activities constitute improper promotion or marketing of an unapproved or improper use, or that they contain untruthful, misleading, or inadequately substantiated statements or claims, such regulatory body could request that we modify our materials or practices, or subject us to regulatory enforcement actions, including the issuance, depending on the regulatory body and the nature of the alleged violation, of a warning letter, injunction, seizure, civil fine and criminal penalties. It is also possible that other federal, state or international enforcement authorities might take action if they consider promotional, marketing or other materials or activities to constitute improper promotion of an unapproved use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement.…
>>>


## 回傳格式（嚴格 JSON 契約，不得夾雜其他文字；一次 Write）
```json
{
  "coverage": {
    "<axis_id>": {
      "status": "found|none|not_applicable",
      "queries_run": ["...", "..."],
      "findings": [
        {"claim": "...", "source": "...", "url": "https://...", "excerpt": "逐字原文…", "excerpt_from": "snippet|page", "as_of": "YYYY-MM-DD", "direction": "+|0|-", "affects": ["moat_trend"]}
      ],
      "note": "",
      "clues": [
        {"claim": "...", "source": "...", "url": "https://...", "as_of": "YYYY-MM-DD", "direction": "+|0|-", "affects": ["moat_trend"], "match_terms": ["預期原文逐字出現的字串", "..."]}
      ]
    }
  }
}
```

`clues` 選填、每軸一個陣列，沒有就整個欄位省略。只在你**找到有網址的線索、但沒讀到頁面而拿不到可逐字複製的原文**時放；程式會打開該網址，在全文裡找 `match_terms` 同時出現的一段原文，找到就升級成帶原文的 finding；找不到（或頁面打不開）就照 `excerpt_from: "snippet"`、`excerpt: null` 的 finding 保留，並標為未核原文。
- 只有 clues、findings 是空的時，`status` 填 `none`（程式核實到原文後會自動改成 `found`）。
- `url` 必須是你在搜尋結果裡實際看到的網址；不得編造、不得猜網址、不得填網站首頁。沒有網址的線索不要放（寫進 note）。已經寫在 findings 的網址不要重複放。
- `match_terms` 放 2～5 個預期原文會逐字出現的字串：金額、比例、專有名詞、引號裡的關鍵詞。照原文可能的寫法填，不要改寫或翻譯；不要放公司名、代號、年份或「營收」「公司」這類到處都有的詞。
- 其餘欄位（`claim`、`source`、`as_of`、`direction`、`affects`）規則同 findings；`as_of` 填你推估的文章發布日，程式讀到頁面發布日會以頁面為準。

寫入路徑：`/Users/ivanchang/financial-analysis-bot/.dd_build/runs/DXCM_20261102/parts/axes_5.json`（用 Write 工具寫一次，不要分次 Edit）。

## 輪次紀律
你只有 WebSearch、WebFetch、Write 三個工具，沒有 Bash。**寫完 part 檔就停止**，不要自己驗證、不要重讀、不要回報長文。驗證由程式做；缺欄程式會把該軸記成缺口，不會叫你重寫。
搜尋：本軸最多 3 次；WebFetch 只在搜尋摘要不足以寫出 as_of 與 claim 時才用，每軸最多 2 次。

回報 ≤50 字：完成幾軸、found/none 各幾軸。
